About MBX Biosciences
MBX Biosciences is a company based in Carmel (United States) founded in 2018.. MBX Biosciences has raised $215.6 million across 4 funding rounds from investors including Orbimed, RA Capital and Driehaus. The company has 43 employees as of December 31, 2024. MBX Biosciences offers products and services including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109. MBX Biosciences operates in a competitive market with competitors including Neurocrine, Crinetics, Zucara Therapeutics, Amolyt Pharma and OMass Therapeutics, among others.
- Headquarter Carmel, United States
- Employees 43 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mbx Biosciences, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-61.92 M-90.16as on Dec 31, 2024
-
EBITDA
$-67.95 M-93.29as on Dec 31, 2024
-
Total Equity Funding
$215.6 M (USD)
in 4 rounds
-
Latest Funding Round
$63.5 M (USD), Series C
Aug 05, 2024
-
Investors
Orbimed
& 10 more
-
Employee Count
43
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MBX Biosciences
MBX Biosciences is a publicly listed company on the NASDAQ with ticker symbol MBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MBX Biosciences
MBX Biosciences offers a comprehensive portfolio of products and services, including Canvuparatide, MBX 1416, MBX 4291, and MBX 2109. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Peptide therapy for treating endocrine disorders effectively.
Advanced treatment for metabolic conditions and related issues.
Peptide-based solution for endocrine and health management.
Innovative peptide for addressing metabolic disorders.
Unlock access to complete
Leadership Team
12 people
Product Management Team
3 people
Finance and Accounting
2 people
Data Analysis and Operations Team
1 people
Operations Team
1 people
Software Development Team
1 people
Accountant Team
1 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of MBX Biosciences
MBX Biosciences has successfully raised a total of $215.6M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $63.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $63.5M
-
First Round
First Round
(01 Jun 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Series C - MBX Biosciences | Valuation | Deep Track Capital | |
| Nov, 2022 | Amount | Series B - MBX Biosciences | Valuation | Wellington | |
| Jul, 2020 | Amount | Series A - MBX Biosciences | Valuation | Frazier Healthcare Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MBX Biosciences
MBX Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Driehaus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location | |
|
Healthcare investment firm focused on novel therapeutics development.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MBX Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MBX Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mbx Biosciences Comparisons
Competitors of MBX Biosciences
MBX Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Zucara Therapeutics, Amolyt Pharma and OMass Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mbx Biosciences
Frequently Asked Questions about MBX Biosciences
When was MBX Biosciences founded?
MBX Biosciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is MBX Biosciences located?
MBX Biosciences is headquartered in Carmel, United States. It is registered at Carmel, California, United States.
Is MBX Biosciences a funded company?
MBX Biosciences is a funded company, having raised a total of $215.6M across 4 funding rounds to date. The company's 1st funding round was a Series A of $34.6M, raised on Jun 01, 2019.
How many employees does MBX Biosciences have?
As of Dec 31, 2024, the latest employee count at MBX Biosciences is 43.
What does MBX Biosciences do?
MBX Biosciences is a developer of drugs for the treatment of rare endocrine diseases. It has developed endocrine drugs including Forteo and Humalog for the treatment of rare diseases. It uses use peptide hormones to regulate many physiological functions including growth, energy utilization, metabolism, gastrointestinal function, and stress responses.
Who are the top competitors of MBX Biosciences?
MBX Biosciences's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
What products or services does MBX Biosciences offer?
MBX Biosciences offers Canvuparatide, MBX 1416, MBX 4291, and MBX 2109.
Is MBX Biosciences publicly traded?
Yes, MBX Biosciences is publicly traded on NASDAQ under the ticker symbol MBX.
Who are MBX Biosciences's investors?
MBX Biosciences has 11 investors. Key investors include Orbimed, RA Capital, Driehaus, Norwest Venture Partners, and Frazier Healthcare Partners.
What is MBX Biosciences's ticker symbol?
The ticker symbol of MBX Biosciences is MBX on NASDAQ.